Resting Energy Expenditure and Substrate Consumption in Cardiac Arrest Patients Under Target Temperature Management
Key facts
- Who runs it
- Tang Ziren
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 1 Jun 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Target Temperature Management Treatment
- Record updated
- 12 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Be admitted to the emergency department of Beijing Chao-yang Hospital, Capital Medical University
- Successfully resuscitated, and are unconscious after restoration of spontaneous circulation (ROSC)
- Be admitted to the intensive care unit (ICU) for advanced life support such as endotracheal intubation after restoration of spontaneous circulation (ROSC)
- Accepted target temperature management (TTM) therapy after restoration of spontaneous circulation (ROSC)
Who cannot take part
- Severe metabolic abnormalities are known: cachexia, thyroid dysfunction, and cancer;
- Age > 18 years old;
- Incomplete clinical data and loss of follow-up
- Traumatic brain injury or cerebrovascular accident revealed by computed tomography (CT);
- Indirect calorimetry measurement is not possible such as sustained oxygen concentration > 70%;
- There were no signs of resuscitation at the time of admission;
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a single-center, prospective, observational study. According to the sample size formula, an estimated 40 cases should be collected, all of whom are from the emergency intensive care unit. After successful cardiopulmonary resuscitation, the enrolled patients will be transferred to the emergency intensive care unit for further standardized target temperature management (TTM). They will be divided into 33 ° C hypothermia group and 36 ° C hypothermia group according to the patient's core body temperature. The baseline data of the patients will be collected at the beginning. After admission to the hospital, they were fasted within 24 hours to reach the target temperature, and then 20kcal/kg/d parenteral nutrition will be given. At selected time points (T0: the initial time point before TTM; T1: the core temperature was reduced to 33 ° C or 36 ° C; T2-T4: 33 ° C or 36 ° C was maintained for 24h, 48h, 72h; T5: the end of rewarming; Tend: the last REE measurement before discharge or death) , various observation indicators will be collected, including resting energy expenditure (REE), glucose oxidation rate, fat oxidation rate, protein oxidation rate, and metabolism of three major nutrients Proportion. Neurological outcomes were followed up 28 days after onset according to the Cerebral Performance Categories (CPC) score.
The 2 groups in the trial
- 33℃ group
Treatment: Target Temperature Management Treatment
- 36℃ group
Treatment: Target Temperature Management Treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 12 August 2026